Documentos relacionados

1. Biomedical research in france and brazil: an analysis of significant differences and ethical issues
2. The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update.
3. The Emerging Role of GLP-1 Receptors in DNA Repair: Implications in Neurological Disorders.
4. Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia.
5. New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review.
6. Anti-Inflammatory Effects of GLP-1R Activation in the Retina.
7. Qué nos ha enseñado y qué nos queda por aprender del estudio PREDIMED
8. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
9. Glucagon and type 2 diabetes: the return of the alpha cell.
10. Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy.